Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** According to the U.S. Department of Health and Human Services (HHS), in 2018, 10.3 million people misused prescription opioids. Of those, 2 million were diagnosed with an Opioid Use Disorder; 47,600 persons died from an opioid overdose. In Missouri in 2017, nearly 2.6 persons died each day from an opioid overdose.

Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Historically, naloxone has only been available in a 0.4 mg single dose vial for intramuscular (IM) injection. A 2 mg / 2 mL prefilled syringe is also available and has been used with an atomizer device to administer naloxone intranasally.

Narcan® Nasal Spray delivers a 4mg dose of naloxone for opiate overdose; the product comes in a two-pak. Available products generally cannot be self-administered.

Pharmacists in Missouri are able to prescribe and dispense naloxone according to protocol upon request. Narcan® Nasal Spray will be available without restriction as a “preferred” product for MO HealthNet participants at risk of harm from an opiate overdose.

Total program savings for the PDL classes will be regularly reviewed.

<table>
<thead>
<tr>
<th>Program-Specific Information:</th>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of Criteria:</td>
<td>☐ Increased risk of ADE</td>
<td>☒ Preferred Drug List</td>
</tr>
<tr>
<td>Data Sources:</td>
<td>☒ Only Administrative Databases</td>
<td>☐ Databases + Prescriber-Supplied</td>
</tr>
</tbody>
</table>

**Setting & Population**

- Drug class for review: Opioid Emergency Reversal Agents
- Age range: All appropriate Mo HealthNet participants

---

SmartPA PDL Proposal Form
© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.
Approval Criteria

- Claim is for a preferred product

Denial Criteria

- Therapy will be denied if no approval criteria are met

Required Documentation

- Laboratory Results:  
  - Progress Notes:  
  - MedWatch Form:  
  - Other:

Disposition of Edit

Denial: Exception Code “0160” (Preferred Drug List Edit)  
Rule Type: PDL

Default Approval Period

3 months

References